September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.
Over the past few years, many pharma brands set out to build a direct-to-patient (DTP) channel. The website went live. A telehealth partner was selected. Pharmacy logistics were set up.
Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.
pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.
Health systems face the pressure of maintaining continuity of care in an environment where supply disruptions and drug shortages persist as concerns.
Editor's Picks
